Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin added to metformin and sulfonylurea in type 2 diabetes
2010-019428-30Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin plus metformin plus sulfonylurea with Placebo plus metformin plus sulfonylurea (2 arms). Primary endpoint: Change in HbA1c from baseline to Week 24/endpoint. Started Jun 2010; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019428-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019428-30.